- Home
- RGC vs TNYA Comparison
RGC vs TNYA Comparison
Compare RGC & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- TNYA
- Stock Information
- Founded
- RGC 2014
- TNYA 2016
- Country
- RGC Hong Kong
- TNYA United States
- Employees
- RGC N/A
- TNYA N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- RGC Health Care
- TNYA Health Care
- Exchange
- RGC Nasdaq
- TNYA Nasdaq
- Market Cap
- RGC 105.3M
- TNYA 119.2M
- IPO Year
- RGC 2021
- TNYA 2021
- Fundamental
- Price
- RGC $4.82
- TNYA $1.40
- Analyst Decision
- RGC
- TNYA Strong Buy
- Analyst Count
- RGC 0
- TNYA 4
- Target Price
- RGC N/A
- TNYA $17.33
- AVG Volume (30 Days)
- RGC 6.7K
- TNYA 3.8M
- Earning Date
- RGC 10-25-2024
- TNYA 03-17-2025
- Dividend Yield
- RGC N/A
- TNYA N/A
- EPS Growth
- RGC N/A
- TNYA N/A
- EPS
- RGC N/A
- TNYA N/A
- Revenue
- RGC N/A
- TNYA N/A
- Revenue This Year
- RGC N/A
- TNYA N/A
- Revenue Next Year
- RGC N/A
- TNYA N/A
- P/E Ratio
- RGC N/A
- TNYA N/A
- Revenue Growth
- RGC N/A
- TNYA N/A
- 52 Week Low
- RGC $3.03
- TNYA $0.99
- 52 Week High
- RGC $32.44
- TNYA $7.01
- Technical
- Relative Strength Index (RSI)
- RGC 44.37
- TNYA 37.13
- Support Level
- RGC $4.81
- TNYA $1.43
- Resistance Level
- RGC $4.95
- TNYA $1.63
- Average True Range (ATR)
- RGC 0.24
- TNYA 0.12
- MACD
- RGC 0.03
- TNYA 0.03
- Stochastic Oscillator
- RGC 19.92
- TNYA 24.59
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.